Novavax, Inc. (0A3S.L)
| Previous close | 58.18 |
| Open | 59.14 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 58.37 - 60.36 |
| 52-week range | 5.68 - 60.36 |
| Volume | |
| Avg. volume | 111,016 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Shah Capital nominates two highly qualified independent director candidates for Novavax
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management’s failure to capitalize on Novavax’s many significant competitive advantages and TAM opportunities The letter highlights that the underperformance is self-inflicted and is the result of reactive leadership and outd
- PR Newswire
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza Combination (CIC) vaccine candidates at the World Vaccine Congress 2024 (WVC) in Washington, DC, April 2 to 4, 2024.
- PR Newswire
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44th Annual Health Care Conference.
